Cell-Therapy and Immunocardiology
Our focus is the development of a new field in cardiology: Immunocardiology.
Cardiac inflammation, which is triggered by the innate and adaptive immunity, plays an important role in the pathogenesis of different forms of heart failure. In strong interaction with the cardioproteomics and the experimental immunocardiology group, the clinical immunocardiology group aims at translating novel immunomodulatory strategies from bench to bedside and at finding novel biomarkers of heart failure. On long-term, we aim to reach patient-differentiated treatment options which are based on their clinical as well as endomyocardial biopsy/ immune profile.
- Analysis of endomyocardial biopsies
- Search for novel diagnostic markers of inflammatory cardiomyopathy and heart failure with preserved ejection fraction
- Identification of monitoring markers of therapy effectiveness
- Clinical trials with immunomodulatory and antiviral therapies